Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc. has demonstrated robust growth in prescription volumes, with a notable 41% sequential increase in October 2025, which surpasses the total prescriptions written in the prior third quarter. The company plans to expand its sales force from 50 to 64 territory managers by early 2026, which is expected to enhance its market coverage and bolster its revenue from products like Xepi within a large untapped market. With a positive trajectory in prescriber adoption and treatment rates projected to rise, Pelthos is well-positioned to capitalize on its innovative product offerings and operational efficiencies, indicating strong potential for future financial performance.

Bears say

Pelthos Therapeutics Inc faces significant challenges that could negatively impact its financial outlook and stock performance. If the company fails to secure adequate reimbursement levels and formulary placements, projected sales and margins may suffer due to slower-than-expected market adoption among healthcare professionals and payers. Additionally, the potential for its clinical-stage products to deliver statistically insignificant results in late-stage trials, along with the risk of regulatory approval failures and increased competition, further exacerbates concerns about revenue growth and overall company value.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.